

Elecsys Anti-HAV II

REF			SYSTEM
08086630190	08086630500	100	cobas e 411 cobas e 601 cobas e 602

English

System information

For **cobas e 411** analyzer: test number 1570

For **cobas e 601** and **cobas e 602** analyzers: Application Code Number 469

Intended use

Immunoassay for the in vitro qualitative detection of total antibodies (IgG and IgM) to the hepatitis A virus (HAV) in human serum and plasma. The assay is used as an aid to detect a past or existing hepatitis A infection or used to determine the presence of antibody response to HAV in vaccine recipients.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

Summary

The hepatitis A virus (HAV) is a non-enveloped single stranded RNA-virus that belongs to the family of picornaviruses. To date, just one human serotype and 6 genotypes have been described, 3 of which infect humans (genotypes I, II and III).¹ Initially, 7 genotypes were described, but subsequent analyses suggest that genotypes II and VII are subtypes of genotype II.² The viral capsid consists of 3 major structural proteins (VP1-VP3) and a fourth putative protein (VP4) that form an immunodominant structure on the surface of the viral particle, which is highly conserved between all genotypes. After vaccination or natural infection, the immune response is directed against this structure.^{1,3}

HAV is one of the most common causes of infectious jaundice and is transmitted by the fecal-oral route. HAV causes acute hepatitis and is not associated with chronic liver disease because the virus does not persist in the organism.^{1,3}

Total anti-HAV (anti-HAV IgM and IgG) is positive at the onset of symptoms and due to the presence of IgM.⁴ After natural infection, anti-HAV IgG can usually be detected early in the course of infection and remains detectable throughout a person's lifetime conferring protection against the disease if the organism is reinfected.^{4,5}

Vaccines against HAV and combined vaccines against hepatitis A and B are available today.^{3,4} Anti-HAV IgG can be detected approximately 2 weeks after vaccination against HAV. In the case of complete immunization, protection usually lasts for many years. To define a protective antibody response, clinical vaccine studies typically used anti-HAV levels of > 20 IU/L, while some studies have used levels of > 10 IU/L.^{5,6,7} A positive anti-HAV result indicates immune protection. However, after vaccination, persons who are anti-HAV negative (< 20 IU/L) might nevertheless have protective levels of antibody. The absolute lower limit of anti-HAV required to prevent HAV infection has not been defined. In vitro studies using cell-culture-derived virus indicate that low levels of antibody (e.g. < 20 IU/L) can be neutralizing.⁸

Assays to detect anti-HAV antibodies are used to determine an existing or past HAV infection or to observe the immune response after HAV vaccination.¹

Test principle

Competition principle. Total duration of assay: 18 minutes.

- 1st incubation: 20 µL of sample; the anti-HAV in the sample binds the added HAV antigen.
- 2nd incubation: After addition of biotinylated antibodies and ruthenium complex⁹-labeled antibodies specific for HAV antigen, together with streptavidin-coated microparticles, the still-free binding sites on the HAV antigens become occupied. The entire complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell/ProCell M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.

- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the reagent barcode or e-barcode.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)₃²⁺)

Reagents - working solutions

The reagent rackpack (M, R1, R2) is labeled as AHAV 2.

- M Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 HAV Ag (gray cap), 1 bottle, 10 mL: HAV Ag (cell culture) 28 U/mL (Roche units); TRIS buffer 20 mmol/L, pH 7.2; preservative.
- R2 Anti-HAV Ab~biotin; anti-HAV Ab~Ru(bpy)₃²⁺ (black cap), 1 bottle, 9 mL: Biotinylated monoclonal anti-HAV antibody (mouse) 0.25 µg/mL; monoclonal anti-HAV antibody (mouse) labeled with ruthenium complex 0.65 µg/mL; TRIS buffer 20 mmol/L, pH 7.2; preservative.

AHAV 2 Cal1 Negative calibrator 1 (white cap), 2 bottles of 1.0 mL each: Anti-HAV negative human serum; preservative.

AHAV 2 Cal2 Positive calibrator 2 (black cap), 2 bottles of 1.0 mL each: Anti-HAV (human) approximately 60 IU/L in human serum; preservative.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Warning

H317 May cause an allergic skin reaction.

Prevention:

P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

Disposal:

Elecsys Anti-HAV II

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

All human material should be considered potentially infectious. All products derived from human blood are prepared exclusively from the blood of donors tested individually and shown to be free from HBsAg and antibodies to HCV and HIV. The testing methods use assays that have been approved by the FDA or that are in compliance with the legal rules applicable to placing in vitro diagnostic medical devices for human use on the market in the European Union.

However, as no testing method can rule out the potential risk of infection with absolute certainty, the material should be handled with the same level of care as a patient specimen. In the event of exposure, the directives of the responsible health authorities should be followed.^{9,10}

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

Reagent handling

The reagents in the kit are ready-for-use and are supplied in bottles compatible with the system.

Calibrators

cobas e 411 analyzer: The calibrators should only be left on the analyzer during calibration at 20-25 °C. After use, close the bottles as soon as possible and store upright at 2-8 °C.

Due to possible evaporation effects, not more than 5 calibration procedures per bottle set should be performed.

cobas e 601 and **cobas e 602** analyzers: Unless the entire volume is necessary for calibration on the analyzers, transfer aliquots of the ready-for-use calibrators into empty snap-cap bottles (CalSet Vials). Attach the supplied labels to these additional bottles. Store the aliquots at 2-8 °C for later use.

Perform **only one** calibration procedure per aliquot.

All information required for correct operation is read in from the respective reagent barcodes.

Please note: Both the vial labels, and the additional labels (if available) contain 2 different barcodes. The barcode between the yellow markers is for **cobas 8000** systems only. If using a **cobas 8000** system, please turn the vial cap 180° into the correct position so the barcode can be read by the system. Place the vial on the instrument as usual.

Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the Elecsys reagent kit **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability of the reagent rackpack	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on the analyzers	8 weeks

Stability of the calibrators	
unopened at 2-8 °C	up to the stated expiration date
after opening at 2-8 °C	8 weeks
on cobas e 411 at 20-25 °C	up to 6 hours
on cobas e 601 and cobas e 602 at 20-25 °C	use once only

Store calibrators **upright** in order to prevent the calibrator solution from adhering to the snap-cap.

Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, Na-heparin, K₂-EDTA, K₃-EDTA, ACD, CPD, CP2D, CPDA and Na-citrate plasma.

Plasma tubes containing separating gel can be used.

Criterion: Correct assignment of positive and negative samples. Samples with a COI (cutoff index) > 1.0: ± 20 % recovery compared to serum reference; samples with a COI ≤ 1.0: ± 0.20 COI recovery compared to serum reference.

Stable for 6 days at 20-25 °C, 14 days at 2-8 °C, 3 months at -20 °C (± 5 °C). The samples may be frozen 5 times.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates and thawed samples before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples, calibrators and controls are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

The performance of the Elecsys Anti-HAV II assay has not been established with cadaveric samples or body fluids other than serum and plasma.

Materials provided

- See "Reagents – working solutions" section for reagents.
- 2 x 6 bottle labels

Materials required (but not provided)

- [REF 08086672190](#), PreciControl Anti-HAV II, for 8 x 1.3 mL
- [REF 11776576322](#), CalSet Vials, 2 x 56 empty bottles with snap-caps
- General laboratory equipment
- cobas e** analyzer

Additional materials for the **cobas e 411** analyzer:

- [REF 11662988122](#), ProCell, 6 x 380 mL system buffer
- [REF 11662970122](#), CleanCell, 6 x 380 mL measuring cell cleaning solution
- [REF 11930346122](#), Elecsys SysWash, 1 x 500 mL washwater additive
- [REF 11933159001](#), Adapter for SysClean
- [REF 11706802001](#), AssayCup, 60 x 60 reaction cups
- [REF 11706799001](#), AssayTip, 30 x 120 pipette tips
- [REF 11800507001](#), Clean-Liner

Additional materials for **cobas e 601** and **cobas e 602** analyzers:

- [REF 04880340190](#), ProCell M, 2 x 2 L system buffer
- [REF 04880293190](#), CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF 03023141001](#), PC/CC-Cups, 12 cups to prewarm ProCell M and CleanCell M before use
- [REF 03005712190](#), ProbeWash M, 12 x 70 mL cleaning solution for run finalization and rinsing during reagent change
- [REF 03004899190](#), PreClean M, 5 x 600 mL detection cleaning solution
- [REF 12102137001](#), AssayTip/AssayCup, 48 magazines x 84 reaction cups or pipette tips, waste bags
- [REF 03023150001](#), WasteLiner, waste bags
- [REF 03027651001](#), SysClean Adapter M

Additional materials for all analyzers:

- [REF 11298500316](#), ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

Elecsys Anti-HAV II

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use. Read in the test-specific parameters via the reagent barcode. If in exceptional cases the barcode cannot be read, enter the 15-digit sequence of numbers.

cobas e 601 and **cobas e 602** analyzers: PreClean M solution is necessary.

Bring the cooled reagents to approximately 20 °C and place on the reagent disk (20 °C) of the analyzer. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the bottles.

Place the calibrators in the sample zone.

All the information necessary for calibrating the assay is automatically read into the analyzer.

After calibration has been performed, store the calibrators at 2-8 °C or discard (**cobas e 601** and **cobas e 602** analyzers).

Calibration

Traceability: The Elecsys Anti-HAV II assay is traceable to the "Second International Standard for Anti-Hepatitis A, immunoglobulin, human", NIBSC code 97/646 of the NIBSC (National Institute for Biological Standards and Control) via method comparison to the first generation Elecsys Anti-HAV assay as reference.

Calibration frequency: Calibration must be performed once per reagent lot using AHAV 2 Cal1, AHAV 2 Cal2 and fresh reagent (i.e. not more than 24 hours since the reagent kit was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 1 month (28 days) when using the same reagent lot
- after 7 days (when using the same reagent kit on the analyzer)
- as required: e.g. quality control findings outside the defined limits

Quality control

For quality control, use PreciControl Anti-HAV II.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per reagent kit, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the cutoff based on the measurement of AHAV 2 Cal1 and AHAV 2 Cal2.

The result of a sample is given either as reactive or non-reactive as well as in the form of a cutoff-index (COI; signal sample/cutoff).

Interpretation of the results

Numeric result	Result message	Interpretation
COI > 1.0	Non-reactive	Negative for HAV-specific antibodies
COI ≤ 1.0	Reactive	Positive for HAV-specific antibodies

The cutoff of the Elecsys Anti-HAV II assay was determined in a large cohort of blood donors and hospitalized patients using the first generation Elecsys Anti-HAV assay, which has a cutoff of 20 IU/L, as the reference. The cutoff of the Elecsys Anti-HAV II assay thus corresponds to 20 IU/L.

COI values ≤ 1.0 indicate an existing or past hepatitis A infection or the presence of anti-HAV antibodies after hepatitis A vaccination.

Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 1129 μmol/L or ≤ 66 mg/dL
Hemoglobin	≤ 0.621 mmol/L or ≤ 1000 mg/dL
Intralipid	≤ 2000 mg/dL
Biotin	≤ 573 nmol/L or ≤ 140 ng/mL
Rheumatoid factors	≤ 1400 IU/mL
IgG	≤ 7.0 g/dL
IgA	≤ 1.6 g/dL
IgM	≤ 1.0 g/dL

Criterion:

Samples > 1.0 COI ± 20 % recovery

Samples ≤ 1.0 COI ± 0.20 COI recovery

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

Pharmaceutical substances

In vitro tests were performed on 18 commonly used pharmaceuticals. No interference with the assay was found.

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 411 analyzer					
Sample	Mean COI	Repeatability		Intermediate precision	
		SD COI	CV %	SD COI	CV %
Human serum 1	1.37	0.012	0.9	0.018	1.3
Human serum 2	1.11	0.013	1.2	0.016	1.5
Human serum 3	0.940	0.011	1.2	0.016	1.7
Human serum 4	0.661	0.012	1.9	0.021	3.2
Human serum 5	0.010	0.0001	1.4	0.0002	2.2
PC ^{b)} Anti-HAV II 1	1.30	0.013	1.0	0.016	1.3
PC Anti-HAV II 2	0.332	0.005	1.7	0.011	3.2

b) PC = PreciControl

cobas e 601 and cobas e 602 analyzers					
Sample	Mean COI	Repeatability		Intermediate precision	
		SD COI	CV %	SD COI	CV %
Human serum 1	1.42	0.016	1.1	0.028	2.0

Elecsys Anti-HAV II

cobas e 601 and cobas e 602 analyzers					
Sample	Mean COI	Repeatability		Intermediate precision	
		SD COI	CV %	SD COI	CV %
Human serum 2	1.15	0.012	1.1	0.022	1.9
Human serum 3	0.955	0.009	0.9	0.022	2.3
Human serum 4	0.665	0.009	1.3	0.020	2.9
Human serum 5	0.006	0.0002	3.0	0.0002	3.3
PC ^{b)} Anti-HAV II 1	1.30	0.015	1.1	0.024	1.8
PC Anti-HAV II 2	0.339	0.005	1.5	0.009	2.7

Analytical specificity

No cross-reactions with HBV, HCV, HIV, CMV, EBV, HSV, Toxoplasma gondii, Rubella, Mumps/Rubeola, Parvovirus B19 and Treponema pallidum were observed.

Measurements were performed on each of the pathogens listed above using a total of 120 human serum or plasma which were positive for antibodies to the above-mentioned pathogens or contained autoantibodies (ANA).

Clinical data

In the clinical studies, conducted to assess the relative sensitivity and relative specificity of the assay, samples from various international sources were used.

Clinical sensitivity

The relative sensitivity was found to be 100 % in samples from subjects vaccinated against HAV, acutely infected subjects and subjects who had recovered from a natural HAV infection.

	N	Sensitivity %	95 % CI ^{c)} (2-sided) %
Subjects vaccinated against hepatitis A	238	100	98.45-100
Subjects with acute hepatitis A infection	234	100	98.44-100
Subjects recovered from hepatitis A infection	256	100	98.57-100

c) CI = confidence interval

Clinical specificity

A total of 874 confirmed anti-HAV negative samples from subjects with routine requests for anti-HAV testing and 580 samples confirmed anti-HAV negative from blood donors were tested with the Elecsys Anti-HAV II assay.

	N ^{d)}	Specificity %	95 % CI (2-sided) %
Blood donors	577	99.48	98.49-99.89
Subjects with routine request for anti-HAV testing	871	99.66	99.00-99.93

d) Number of subjects with a negative Elecsys Anti-HAV II test result

References

- Hollinger FB, Emerson SU. Hepatitis A virus. In: Fields Virology, Knipe DM, Howley PM (eds), 2007 5th edition, Lippincott Williams and Wilkins, Philadelphia, USA. Chapter 27, pp911-947.
- Lu L, Ching KZ, de Paula SV, et al. Characterization of the complete genomic sequence of genotype II hepatitis A virus (CF53/Berne isolate). J Gen Virol 2004;85:2943-2952.
- Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 2006 Feb;43(2 Suppl 1):S164-172.
- Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006;28:101-111.

- Tilzey, AJ, Palmer SJ, Barrow S, et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992;304:1272-1276.
- Briem H, Safary A. Immunogenicity and Safety in Adults of Hepatitis A Virus Vaccine Administered as a Single Dose With a Booster 6 Months Later. J Med Virol 1994;44:443-445.
- Ambrosch F, Finkel B, Herzog C, et al. Rapid Antibody Response after Vaccination with a Viroosomal Hepatitis A Vaccine. Infection 2004;32:149-152.
- Lemon SM, Binn LN. Serum Neutralizing Antibody Response to Hepatitis A Virus. J Infect Dis 1983;148:1033-1039.
- Occupational Safety and Health Standards: Bloodborne pathogens. (29 CFR Part 1910.1030). Fed. Register.
- Directive 2000/54/EC of the European Parliament and Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets, the product information and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: <https://ec.europa.eu/tools/eudamed>

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPIID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2020, Roche Diagnostics

0123

Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com
+800 5505 6606

